公开(公告)号：US20230201321A1

公开(公告)日：2023-06-29

申请号：US17820432

申请日：2022-08-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Oliver SCHOOR ,  Andrea MAHR

IPC: A61K39/00 ,  G16B25/00 ,  C07K14/64 ,  C07K14/705 ,  C07K16/00 ,  G16B25/10 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68

CPC classification number: A61K39/0011 ,  G16B25/00 ,  C07K14/64 ,  C07K14/70503 ,  C07K16/00 ,  G16B25/10 ,  C07K14/4743 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2809 ,  C12N5/0638 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/57484 ,  G01N33/6872 ,  A61K2039/80 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/40 ,  C12N2310/16 ,  C12Q2600/136 ,  G01N2333/70539

Abstract: The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230192886A1

公开(公告)日：2023-06-22

申请号：US18053705

申请日：2022-11-08

Applicant: Immatics Biotechnologies GmbH ,  Immatics US, Inc.

Inventor： Harpreet SINGH ,  Toni WEINSCHENK ,  Steffen WALTER

IPC: C07K16/30 ,  A61K38/17 ,  A61P35/00

CPC classification number: C07K16/3053 ,  A61K38/1774 ,  A61P35/00

Abstract: A method of treating a patient who has a recurrent cancer that presents a peptide, including administering to the patient a treatment composition comprising an antigen binding molecule that binds to the peptide, in which the patient has received a prior treatment with a pretreatment composition comprising a second antigen binding molecule that binds to a different peptide.

公开(公告)号：US20230181707A1

公开(公告)日：2023-06-15

申请号：US18158604

申请日：2023-01-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  A61P35/00 ,  C12Q1/6886 ,  C12N15/115 ,  C07K16/28 ,  C07K14/74 ,  C07K16/30 ,  G01N33/574 ,  C07K7/08 ,  C07K14/725 ,  C12N5/0783 ,  C07K7/06 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C12Q1/6886 ,  C12N15/115 ,  C07K16/2833 ,  C07K14/70539 ,  C07K16/3076 ,  G01N33/57492 ,  C07K7/08 ,  C07K14/7051 ,  C12N5/0636 ,  C07K7/06 ,  C07K14/4748 ,  C12Q2600/106 ,  G01N2333/70539 ,  A61K39/00 ,  A61K2039/5158 ,  C12N2310/16 ,  C12Q2600/156 ,  C12N2501/50 ,  C07K2319/40

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230116279A1

公开(公告)日：2023-04-13

申请号：US17929347

申请日：2022-09-02

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230094286A1

公开(公告)日：2023-03-30

申请号：US17929344

申请日：2022-09-02

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230035702A1

公开(公告)日：2023-02-02

申请号：US17930891

申请日：2022-09-09

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K7/06 ,  C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/30 ,  C07K16/28 ,  C12N15/10 ,  A61K39/00 ,  C07K14/54 ,  G01N33/574 ,  C12N5/0783 ,  C12N15/115 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230024554A1

公开(公告)日：2023-01-26

申请号：US17847987

申请日：2022-06-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Christoph SCHRAEDER ,  Heiko SCHUSTER ,  Lena Katharina FREUDENMANN ,  Valentina GOLDFINGER ,  Daniel Johannes KOWALEWSKI ,  Sara YOUSEF ,  Timo MANZ ,  Vedrana MIJOSEK ,  Michael ROEMER ,  Toni WEINSCHENK

IPC: G01N33/543 ,  G01N21/552 ,  G16B20/30 ,  C07K7/06 ,  C07K7/08 ,  C07K16/28 ,  C12N5/0783

Abstract: The present invention relates to a method of characterizing the binding characteristics between a peptide of interest and MHC molecules of a given cell type, the method comprising the steps of: (i) Providing two or more cells characterized by displaying, on their surface, MHC molecules, (ii) dispensing the two or more cells in two or more vessels, so that each vessel comprises one or more cells, (iii) adding, to the different vessels, different variants of a peptide of interest, wherein the variants of said peptide are labeled and have the same amino acid sequence, yet differ from one another in the type of labeling and their concentration, and exposing the cells thereto so as to form, in the different vessels, peptide-MHC complexes on the surface of the cells, (iv) isolating the thus formed peptide-MHC complexes and (v) determining the concentration of the different peptide-MHC complexes formed (FIG. 1).

公开(公告)号：US20220372104A1

公开(公告)日：2022-11-24

申请号：US17832383

申请日：2022-06-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH ,  Gisela SCHIMMACK ,  Michael ROEMER

IPC: C07K14/725 ,  C12N5/0783 ,  A61P35/00 ,  G01N33/574 ,  C07K16/28 ,  C07K14/74 ,  A61K35/17 ,  A61K9/19 ,  A61K39/00 ,  G16B25/10 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220363729A1

公开(公告)日：2022-11-17

申请号：US17860803

申请日：2022-07-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K14/74 ,  C07K16/30 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/10 ,  A61K39/00 ,  C12N15/115 ,  G01N33/574 ,  A61P35/00 ,  C07K16/28 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220362363A1

公开(公告)日：2022-11-17

申请号：US17852207

申请日：2022-06-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Sabrina KUTTRUFF-COQUI ,  Toni WEINSCHENK ,  Jens FRITSCHE ,  Steffen WALTER ,  Norbert HILF ,  Oliver SCHOOR ,  Colette SONG ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  C07K16/28 ,  C12Q1/6886

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.